Literature DB >> 27027851

Systematic review of antibiotic treatment for acute calculous cholecystitis.

A H van Dijk1, P R de Reuver2, T N Tasma1, S van Dieren1,3, T J Hugh4, M A Boermeester1.   

Abstract

BACKGROUND: Intravenous antibiotics are frequently used in the initial management of acute calculous cholecystitis (ACC), although supportive care alone preceding delayed elective cholecystectomy may be sufficient. This systematic review assessed the success rate of antibiotics in the treatment of ACC.
METHODS: A systematic search of MEDLINE, Embase and Cochrane Library databases was performed. Primary outcomes were the need for emergency intervention and recurrence of ACC after initial non-operative management of ACC. Risk of bias was assessed. Pooled event rates were calculated using a random-effects model.
RESULTS: Twelve randomized trials, four prospective and ten retrospective studies were included. Only one trial including 84 patients compared treatment with antibiotics to that with no antibiotics; there was no significant difference between the two groups in terms of length of hospital stay and morbidity. Some 5830 patients with ACC were included, of whom 2997 had early cholecystectomy, 2791 received initial antibiotic treatment, and 42 were treated conservatively. Risk of bias was high in most studies, and all but three studies had a low level of evidence. For randomized studies, pooled event rates were 15 (95 per cent c.i. 10 to 22) per cent for the need for emergency intervention and 10 (5 to 20) per cent for recurrence of ACC. The pooled event rate for both outcomes combined was 20 (13 to 30) per cent.
CONCLUSION: Antibiotics are not indicated for the conservative management of ACC or in patients scheduled for cholecystectomy.
© 2016 BJS Society Ltd Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27027851     DOI: 10.1002/bjs.10146

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  Antibiotic administration after cholecystectomy for acute mild-moderate cholecystitis: a PRISMA-compliant meta-analysis.

Authors:  Davide La Regina; Matteo Di Giuseppe; Stefano Cafarotti; Andrea Saporito; Marcello Ceppi; Francesco Mongelli; Florian Bihl; Ruben Carlo Balzarotti Canger; Antonjacopo Ferrario di Tor Vajana
Journal:  Surg Endosc       Date:  2018-10-16       Impact factor: 4.584

2.  Human Bile Reduces Antimicrobial Activity of Selected Antibiotics against Enterococcus faecalis and Escherichia coli In Vitro.

Authors:  Beatrix Wulkersdorfer; David Jaros; Sabine Eberl; Stefan Poschner; Walter Jäger; Enrico Cosentini; Markus Zeitlinger; Richard Schwameis
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

Review 3.  Acute calculous cholecystitis: Review of current best practices.

Authors:  Carlos Augusto Gomes; Cleber Soares Junior; Salomone Di Saverio; Massimo Sartelli; Michael Denis Kelly; Camila Couto Gomes; Felipe Couto Gomes; Lívia Dornellas Corrêa; Camila Brandão Alves; Samuel de Fádel Guimarães
Journal:  World J Gastrointest Surg       Date:  2017-05-27

4.  [Emergency Surgery and Trauma Care During COVID-19 Pandemic. Recommendations of the Spanish Association of Surgeons].

Authors:  José Manuel Aranda-Narváez; Luis Tallón-Aguilar; Felipe Pareja-Ciuró; Gonzalo Martín-Martín; Antonio Jesús González-Sánchez; Ignacio Rey-Simó; Gonzalo Tamayo-Medel; Carlos Yánez-Benítez; David Costa-Navarro; Soledad Montón-Condón; Salvador Navarro-Soto; Fernando Turégano-Fuentes; María Dolores Pérez-Díaz; José Ceballos-Esparragón; José María Jover-Navalón; José María Balibrea; Salvador Morales-Conde
Journal:  Cir Esp (Engl Ed)       Date:  2020-04-29

5.  The COVID-19 conundrum: SARS-CoV-2 is not present in bile.

Authors:  T Kabir; S Ngaserin; F H Koh; J Huang; B C Ong; M H Chew
Journal:  Br J Surg       Date:  2020-07-20       Impact factor: 6.939

Review 6.  Acute acalculous cholecystitis in children.

Authors:  Dimitri Poddighe; Vitaliy Sazonov
Journal:  World J Gastroenterol       Date:  2018-11-21       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.